{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:40:28Z","timestamp":1792572028625,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/bjc.2016.435","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T21:02:17Z","timestamp":1485291737000},"page":"455-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)"],"prefix":"10.1038","volume":"116","author":[{"given":"Kristina","family":"Lindemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"\u00c5vall-Lundqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"dePont Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine","family":"Woie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten","family":"Kalling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Auranen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seija","family":"Grenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hoegberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tone","family":"Skeie-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Hjerpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"D\u00f8rum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"issue":"21","key":"BFbjc2016435_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30 (21): 2654\u20132663.","journal-title":"J Clin Oncol"},{"issue":"2","key":"BFbjc2016435_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1006\/gyno.1996.0030","volume":"60","author":"S Batra","year":"1996","unstructured":"Batra S, Iosif CS (1996) Elevated concentrations of antiestrogen binding sites in membrane fractions of human ovarian tumors. Gynecol Oncol 60 (2): 228\u2013232.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"BFbjc2016435_CR3","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","volume":"23","author":"M Brundage","year":"2012","unstructured":"Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer\u2014results from the CALYPSO trial. Ann Oncol 23 (8): 2020\u20132027.","journal-title":"Ann Oncol"},{"issue":"11","key":"BFbjc2016435_CR4","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/sj.bjc.6601787","volume":"90","author":"A Buda","year":"2004","unstructured":"Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C (2004) Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 90 (11): 2112\u20132117.","journal-title":"Br J Cancer"},{"key":"BFbjc2016435_CR5","unstructured":"Cancer Therapy Evaluation Program (1992) Common Terminology Criteria for Adverse Events (CTCAE) Version 1.0."},{"issue":"2","key":"BFbjc2016435_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/annonc\/mdf038","volume":"13","author":"A du Bois","year":"2002","unstructured":"du Bois A, Meier W, Luck HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, Richter B, Wagner U (2002) Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 13 (2): 251\u2013257.","journal-title":"Ann Oncol"},{"key":"BFbjc2016435_CR7","volume-title":"The EORTC QLQ-C30 Scoring Manual","author":"PMAN Fayers","year":"2001","unstructured":"Fayers PM AN, Bjordal K, Groenvold M, Curran D, Bottomley A on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 Scoring Manual 3rd edn. Brussels: European Organisation for Research and Treatment of Cancer."},{"issue":"Suppl 2","key":"BFbjc2016435_CR8","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1111\/IGC.0b013e3181bf7fb8","volume":"19","author":"M Friedlander","year":"2009","unstructured":"Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A, Donovan HS, Miller B, King M (2009) Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory\/resistant ovarian cancer. Int J Gynecol Cancer 19 (Suppl 2): S44\u2013S48.","journal-title":"Int J Gynecol Cancer"},{"issue":"14","key":"BFbjc2016435_CR9","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (14): 3312\u20133322.","journal-title":"J Clin Oncol"},{"issue":"2","key":"BFbjc2016435_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","volume":"36","author":"ME Gore","year":"1990","unstructured":"Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36 (2): 207\u2013211.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"BFbjc2016435_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O","volume":"68","author":"KD Hatch","year":"1991","unstructured":"Hatch KD, Beecham JB, Blessing JA, Creasman WT (1991) Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 (2): 269\u2013271.","journal-title":"Cancer"},{"issue":"3","key":"BFbjc2016435_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 33 (3): 244\u2013250.","journal-title":"J Clin Oncol"},{"issue":"3","key":"BFbjc2016435_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1006\/gyno.2001.6199","volume":"81","author":"CM Lakusta","year":"2001","unstructured":"Lakusta CM, Atkinson MJ, Robinson JW, Nation J, Taenzer PA, Campo MG (2001) Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol 81 (3): 490\u2013495.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"BFbjc2016435_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1701-2163(16)30609-0","volume":"26","author":"T Le","year":"2004","unstructured":"Le T, Leis A, Pahwa P, Wright K, Ali K, Reeder B, Kinderchuck M, Ward K (2004) Quality of life evaluations of caregivers of ovarian cancer patients during chemotherapy treatment. J Obstet Gynaecol Can 26 (7): 627\u2013631.","journal-title":"J Obstet Gynaecol Can"},{"key":"BFbjc2016435_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/2193-1801-2-391","volume":"2","author":"CK Lee","year":"2013","unstructured":"Lee CK, Gebski VJ, Coates AS, Veillard AS, Harvey V, Tattersall MH, Byrne MJ, Brigham B, Forbes J, Simes RJ Australia, New Zealand Breast Cancer Trials G (2013) Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. Springerplus 2: 391.","journal-title":"Springerplus"},{"issue":"2","key":"BFbjc2016435_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/annonc\/mdr149","volume":"23","author":"A Lortholary","year":"2012","unstructured":"Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D, Pujade-Lauraine E France Gg (2012) Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 23 (2): 346\u2013352.","journal-title":"Ann Oncol"},{"issue":"1","key":"BFbjc2016435_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1006\/gyno.1996.0181","volume":"62","author":"M Markman","year":"1996","unstructured":"Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B (1996) Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 62 (1): 4\u20136.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"BFbjc2016435_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9 (3): 389\u2013393.","journal-title":"J Clin Oncol"},{"issue":"1","key":"BFbjc2016435_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1524-4733.2008.00405.x","volume":"12","author":"L McKenzie","year":"2009","unstructured":"McKenzie L, van der Pol M (2009) Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health 12 (1): 167\u2013171.","journal-title":"Value Health"},{"issue":"19","key":"BFbjc2016435_CR20","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr., Marciniack M, Naumann RW, Secord AA (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25 (19): 2811\u20132818.","journal-title":"J Clin Oncol"},{"issue":"2","key":"BFbjc2016435_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","volume":"41","author":"D Osoba","year":"2005","unstructured":"Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J Quality of Life Committee of the NC (2005) Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41 (2): 280\u2013287.","journal-title":"Eur J Cancer"},{"issue":"32","key":"BFbjc2016435_CR22","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","volume":"33","author":"AM Poveda","year":"2015","unstructured":"Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, Witteveen P, Bamias A, Scotto N, Mitchell L, Pujade-Lauraine E (2015) Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. J Clin Oncol 33 (32): 3836\u20133838.","journal-title":"J Clin Oncol"},{"issue":"13","key":"BFbjc2016435_CR23","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32 (13): 1302\u20131308.","journal-title":"J Clin Oncol"},{"issue":"19","key":"BFbjc2016435_CR24","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","volume":"26","author":"J Sehouli","year":"2008","unstructured":"Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W (2008) Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26 (19): 3176\u20133182.","journal-title":"J Clin Oncol"},{"issue":"1","key":"BFbjc2016435_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/JCO.2001.19.1.220","volume":"19","author":"AM Stiggelbout","year":"2001","unstructured":"Stiggelbout AM, de Haes JC (2001) Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol 19 (1): 220\u2013230.","journal-title":"J Clin Oncol"},{"issue":"13","key":"BFbjc2016435_CR26","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","volume":"32","author":"MR Stockler","year":"2014","unstructured":"Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E (2014) Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32 (13): 1309\u20131316.","journal-title":"J Clin Oncol"},{"issue":"6","key":"BFbjc2016435_CR27","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","volume":"15","author":"W ten Bokkel Huinink","year":"1997","unstructured":"ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 (6): 2183\u20132193.","journal-title":"J Clin Oncol"},{"issue":"3","key":"BFbjc2016435_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3): 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"BFbjc2016435_CR29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/IGC.0b013e3181daaf59","volume":"20","author":"I Vergote","year":"2010","unstructured":"Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG (2010) Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer 20 (5): 772\u2013780.","journal-title":"Int J Gynecol Cancer"},{"key":"BFbjc2016435_CR30","doi-asserted-by":"crossref","unstructured":"Williams C, Simera I, Bryant A (2010) Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev, (3): CD001034.","DOI":"10.1002\/14651858.CD001034.pub2"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2016435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016435","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:36:10Z","timestamp":1684416970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2016435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFbjc2016435"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.435","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,24]]},"assertion":[{"value":"1 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}